US Drug Recall Register
Class III · Low risk Terminated Initiated Jun 27, 2023 (3 years ago)

Amlodipine Besylate Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Subpotent Drug: Out-of-Specification test results observed in assay test at 21-month long term stability study.

What was recalled

Amlodipine Besylate Tablets, USP 10 mg, 1000-count bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 U.S, Manufactured by: Lupin Limited, Aurangabad 431 210 India, NDC 68180-721-03

Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
68180-721-03
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0899-2023

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Amlodipine recalls

See all
Class II · Moderate risk Ongoing

Amlodipine and Olmesartan Medoxomil Tablets

Reason Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications

Ascend Laboratories, LLC D-0712-2026
Class II · Moderate risk Ongoing

Amlodipine and Olmesartan Medoxomil Tablets

Reason Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications

Ascend Laboratories, LLC NDC 67877-501-30 D-0556-2026
Class II · Moderate risk Terminated

Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg

Reason Labeling: Incorrect or Missing Lot and/or Exp Date: released with wrong expiry date as Feb.2027 instead of Jan.2027

Lupin Pharmaceuticals Inc. NDC 68180-755-01 D-0542-2025